ATE404221T1 - Antikörper gegen il6 zur vorbeugung und behandlung entzündlicher darmerkrankungen - Google Patents

Antikörper gegen il6 zur vorbeugung und behandlung entzündlicher darmerkrankungen

Info

Publication number
ATE404221T1
ATE404221T1 AT99928448T AT99928448T ATE404221T1 AT E404221 T1 ATE404221 T1 AT E404221T1 AT 99928448 T AT99928448 T AT 99928448T AT 99928448 T AT99928448 T AT 99928448T AT E404221 T1 ATE404221 T1 AT E404221T1
Authority
AT
Austria
Prior art keywords
inflammatory bowel
bowel disease
treating inflammatory
preventing
antibodies against
Prior art date
Application number
AT99928448T
Other languages
English (en)
Inventor
John Kink
Katherine Worledge
Douglas Stafford
Original Assignee
Ophidian Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ophidian Pharm Inc filed Critical Ophidian Pharm Inc
Application granted granted Critical
Publication of ATE404221T1 publication Critical patent/ATE404221T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/11—Immunoglobulins specific features characterized by their source of isolation or production isolated from eggs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/23—Immunoglobulins specific features characterized by taxonomic origin from birds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/81—Drug, bio-affecting and body treating compositions involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, immunotolerance, or anergy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/85—Reproductive organs or embryos
    • Y10S530/852—Sperm
    • Y10S530/853—Ovary; eggs; embryos
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/861—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving IgG3, IgG4, IgA, or IgY

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT99928448T 1998-06-10 1999-06-07 Antikörper gegen il6 zur vorbeugung und behandlung entzündlicher darmerkrankungen ATE404221T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/095,535 US6395273B1 (en) 1998-06-10 1998-06-10 Prevention and treatment of inflammatory bowel disease
US09/325,825 US6663864B1 (en) 1998-06-10 1999-06-04 Antibodies to cytokines in the prevention and treatment of inflammatory bowel disease

Publications (1)

Publication Number Publication Date
ATE404221T1 true ATE404221T1 (de) 2008-08-15

Family

ID=22252452

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99928448T ATE404221T1 (de) 1998-06-10 1999-06-07 Antikörper gegen il6 zur vorbeugung und behandlung entzündlicher darmerkrankungen

Country Status (5)

Country Link
US (3) US6395273B1 (de)
EP (1) EP2033658A1 (de)
AT (1) ATE404221T1 (de)
CA (1) CA2334471A1 (de)
DE (1) DE69939316D1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6395273B1 (en) * 1998-06-10 2002-05-28 Promega Corporation Prevention and treatment of inflammatory bowel disease
US20060263357A1 (en) 2005-05-05 2006-11-23 Tedder Thomas F Anti-CD19 antibody therapy for autoimmune disease
TW200831528A (en) 2006-11-30 2008-08-01 Astrazeneca Ab Compounds
CA2681582C (en) * 2007-03-30 2015-07-14 Amgen Inc. Methods of treating bowel disorders
WO2009020748A2 (en) * 2007-07-16 2009-02-12 Avaxia Biologics, Inc. Antibody therapy for modulating function of intestinal receptors
WO2009046168A1 (en) * 2007-10-02 2009-04-09 Avaxia Biologics, Inc. Antibody therapy for use in the digestive tract
US9566297B2 (en) * 2009-02-17 2017-02-14 Novelmed Therapeutics, Inc. Methods and compositions for inhibiting cellular proliferation and surgical adhesion
ES2581488T3 (es) * 2009-04-08 2016-09-06 Lipum Ab Nuevos métodos para el tratamiento de enfermedades inflamatorias
US8682440B2 (en) 2009-08-03 2014-03-25 Incube Labs, Llc Swallowable capsule and method for stimulating incretin production within the intestinal tract
AU2010306563B2 (en) * 2009-10-15 2013-11-28 Circle 33, Llc Antibody therapeutics with local activity in the digestive tract
US8721620B2 (en) 2009-12-24 2014-05-13 Rani Therapeutics, Llc Swallowable drug delivery device and methods of drug delivery
JP5367184B2 (ja) * 2010-06-10 2013-12-11 エドバイオテック カンパニー リミテッド 腸内コレステロール吸収抑制を通じた高脂血症及び肥満抑制用組成物
US8846040B2 (en) 2010-12-23 2014-09-30 Rani Therapeutics, Llc Therapeutic agent preparations comprising etanercept for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9284367B2 (en) 2010-12-23 2016-03-15 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9283179B2 (en) 2010-12-23 2016-03-15 Rani Therapeutics, Llc GnRH preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8969293B2 (en) 2010-12-23 2015-03-03 Rani Therapeutics, Llc Therapeutic agent preparations comprising exenatide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8809269B2 (en) 2010-12-23 2014-08-19 Rani Therapeutics, Llc Therapeutic agent preparations comprising insulin for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9402806B2 (en) 2010-12-23 2016-08-02 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9861683B2 (en) 2010-12-23 2018-01-09 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9259386B2 (en) 2010-12-23 2016-02-16 Rani Therapeutics, Llc Therapeutic preparation comprising somatostatin or somatostatin analogoue for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8980822B2 (en) 2010-12-23 2015-03-17 Rani Therapeutics, Llc Therapeutic agent preparations comprising pramlintide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9402807B2 (en) 2010-12-23 2016-08-02 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US10639272B2 (en) 2010-12-23 2020-05-05 Rani Therapeutics, Llc Methods for delivering etanercept preparations into a lumen of the intestinal tract using a swallowable drug delivery device
US9629799B2 (en) 2010-12-23 2017-04-25 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9415004B2 (en) 2010-12-23 2016-08-16 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8734429B2 (en) 2010-12-23 2014-05-27 Rani Therapeutics, Llc Device, system and methods for the oral delivery of therapeutic compounds
US8926980B2 (en) 2011-07-11 2015-01-06 Camas Incorporated Compositions against bacterial toxins
US11077112B2 (en) 2015-09-29 2021-08-03 ProdrugXtend Pty Ltd Formulation and treatment methods
JP7630906B2 (ja) 2017-02-01 2025-02-18 イェール・ユニヴァーシティー 利尿薬耐性の治療
SG11202006157VA (en) 2018-01-05 2020-07-29 Corvidia Therapeutics Inc Methods for treating il-6 mediated inflammation without immunosuppression
GB201812262D0 (en) * 2018-07-27 2018-09-12 Micropharm Ltd Therapies for treating proctitis

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4477432A (en) 1981-05-01 1984-10-16 Cutter Laboratories, Inc. Oral immune globulin
US4748018A (en) * 1984-02-07 1988-05-31 Stolle Research & Development Corp. Method of passive immunization of mammals using avian antibody
DE19975063I2 (de) 1984-03-06 2005-08-18 Dainippon Pharmaceutical Co DNS den menschlichen Tumornekrosisfaktor kodierendund das menschliche Tumornekronisfaktor-Polypepti d.
US5672347A (en) 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
US4677064A (en) 1984-11-09 1987-06-30 Cetus Corporation Human tumor necrosis factor
WO1986003751A2 (en) 1984-12-21 1986-07-03 Biogen N.V. Purification, production and use of tumor necrosis factors
GB8519848D0 (en) 1985-08-07 1985-09-11 Schweiz Rotes Kreuz Treatment of chronic inflammatory disease
US4870163A (en) 1985-08-29 1989-09-26 New York Blood Center, Inc. Preparation of pure human tumor necrosis factor and hybridomas producing monoclonal antibodies to human tumor necrosis factor
EP0225254B1 (de) 1985-11-25 1994-03-16 Ghen Corporation Einen spezifischen Antikörper enthaltender Stoff aus Eiern, Verfahren zu dessen Herstellung und seine Anwendung
GB9023783D0 (en) * 1990-11-01 1990-12-12 Celltech Ltd Pharmaceutical product
GB9028123D0 (en) 1990-12-28 1991-02-13 Erba Carlo Spa Monoclonal antibodies against human tumor necrosis factor alpha
AU1531492A (en) 1991-02-14 1992-09-15 Rockefeller University, The Method for controlling abnormal concentration tnf alpha in human tissues
US5698195A (en) * 1991-03-18 1997-12-16 New York University Medical Center Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies
US5656272A (en) 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
US5334380A (en) * 1991-09-27 1994-08-02 Board Of Regents, The University Of Texas System Anti-endotoxin, interleukin-1 receptor antagonist and anti-tumor necrosis factor antibody with arginine-free formulations for the treatment of hypotension
FI944549L (fi) 1992-04-02 1994-11-30 Smithkline Beecham Corp Allergisten ja tulehdussairauksien hoidossa käyttökelpoiset yhdisteet
US5753228A (en) 1992-08-25 1998-05-19 Arizona Board Of Regents On Behalf Of The University Of Arizona Method of treating parasitosis by the enteral administration of hyperimmune hen egg yolk antibodies
ATE204299T1 (de) 1993-03-05 2001-09-15 Bayer Ag Humane monoklonale anti-tnf alpha antikörper
US5420253A (en) 1993-09-09 1995-05-30 Willmar Poultry Company, Inc. Method for purifying egg yolk immunoglobulins
US5707622A (en) 1994-03-03 1998-01-13 Genentech, Inc. Methods for treating ulcerative colitis
US5604231A (en) 1995-01-06 1997-02-18 Smith; Carr J. Pharmaceutical compositions for prevention and treatment of ulcerative colitis
WO1996033204A1 (en) 1995-04-20 1996-10-24 The Kennedy Institute Of Rheumatology Multiple administrations of anti-tnf antibody
US5853697A (en) 1995-10-25 1998-12-29 The United States Of America, As Represented By The Department Of Health & Human Services Methods of treating established colitis using antibodies against IL-12
US5756499A (en) * 1996-01-11 1998-05-26 Smithkline Beecham Corporation Substituted imidazole compounds
US5772999A (en) 1996-07-30 1998-06-30 Dcv Biologics, L.P. Method of preventing, countering, or reducing NSAID-induced gastrointestinal damage by administering milk or egg products from hyperimmunized animals
WO1998014209A1 (en) 1996-10-02 1998-04-09 Ovimmune, Inc. Oral administration of chicken yolk antibodies to treat disease
US6395273B1 (en) * 1998-06-10 2002-05-28 Promega Corporation Prevention and treatment of inflammatory bowel disease

Also Published As

Publication number Publication date
US6663864B1 (en) 2003-12-16
US7261891B2 (en) 2007-08-28
EP2033658A1 (de) 2009-03-11
CA2334471A1 (en) 1999-12-16
DE69939316D1 (de) 2008-09-25
US6395273B1 (en) 2002-05-28
US20050053604A1 (en) 2005-03-10

Similar Documents

Publication Publication Date Title
DE69939316D1 (de) Antikörper gegen il6 zur vorbeugung und behandlung entzündlicher darmerkrankungen
ATE510562T1 (de) Anti-ailim antikörper zur behandlung von crohn's
CY2020003I1 (el) Anti-il-12 αντισωματα, συνθεσεις, μεθοδοι και χρησεις για την θεραπευτικη αγωγη της παθολογιας του crohn
CY1111912T1 (el) Μεθοδος αναστολης της δραστηριοτητας των οστεοκλαστων
ATE253376T1 (de) Polynukleotid-impfstoff, vorzugsweise zur behandlung der atemkrankheit bei rindern
DE60143660D1 (de) Vorrichtung zur behandlung des nasen-rachenraumes
BR0110975A (pt) Tratamento profilático e terapêutico de doenças infecciosas ou outras doenças com compostos à base de mono- e disacarìdeos
ATE246500T1 (de) Verwendung von anti-mikrotubuli mitteln zur behandlung von entzündlichen erkrankungen der atemwege
FR10C0016I2 (fr) Procedes et compositions s'appliquant au traitement de la glomerulonephrite
ATE319474T1 (de) Behandlung von autoimmunkrankheiten durch orale verabreichung von autoantigenen
ATE542801T1 (de) Zur behandlung von neoplastischen krankheiten, entzündlichen erkrankungen und erkrankungen des immunsystems geeignete 2,4-pyrimidindiamine
DK2853272T3 (da) Terapeutisk anvendelse af anti-CS1-antistoffer
FI943974A7 (fi) Kotieläinten ihotulehdusten käsittelyvesi
NO894222L (no) Fremgangsmaater for behandling og profylakse av pneumocytis carinii pneumoni og andre sykdommer og forbindelser og formuleringer for anvendelse i nevnte metoder.
DE69004189D1 (de) Anordnungen zur behandlung menschlichen oder tierischen abfalls mittels mikrowellen.
DE3851971D1 (de) Verwendung antigener Substanzen zur Prophylaxe oder Therapie von Störungen und Krankheiten im Verdauungstrakt von Tieren und Menschen.
ATE326534T1 (de) Methode zur behandlung von muskelkrankheiten
DE50014268D1 (de) Zusammensetzung, enthaltend bakterielle antigene, zum vorbeugen und behandeln von allergischen erkrankungen
ATE374037T1 (de) Pimenta-extrakt enthaltende zusammensetzung in behandlungsverfahren für wassertiere
DE69827814D1 (de) 8a-AZALIDEN ALS ANTIMIKROBIELLE AGENTEN
FR2676622B1 (fr) Prothese capillaire et procede de traitement des calvities au moyen de cette prothese.
DE69112718D1 (de) Verfahren und Zusammensetzung zur Behandlung von tierischen Exkrementen.
DE3765916D1 (de) Sonde zur einfuehrung in den verdauungs- oder ausscheidungstrakt des menschlichen oder tierischen koerpers, insbesondere lithotriptor-sonde.
IT7828549A0 (it) Composizione terapeutica per il trattamento di infezioni e malattie di animali da allevamento.
NO304631B1 (no) FremgangsmÕte for fremstilling av overflatekoagulert for til kjµledyr, oppdrettsfisk pelsdyr fugler og andre dyr ved overflatekoagulering

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties